Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Chief Operating Officer | July 21, 2020 | July 23, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date July 21, 2020 · Filed July 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 220,867 |
Ending reported balance
After 2020-07-22 transaction · row 15
15 source rows · reconciled sequenceRow 1 · 2020-07-21 · Exercise / conversion · Acquired 300 · Balance 221,167 Row 2 · 2020-07-21 · Sale · Disposed 300 · Balance 220,867 F1: On July 21, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 300 shares in multiple trades at prices ranging from $65.00 to $65.11. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2020-07-21 · Exercise / conversion · Acquired 3,021 · Balance 223,888 Row 4 · 2020-07-21 · Sale · Disposed 3,021 · Balance 220,867 F2: On July 21, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 3,021 shares in multiple trades at prices ranging from $65.00 to $65.31. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Row 5 · 2020-07-22 · Exercise / conversion · Acquired 8,426 · Balance 229,293 Row 6 · 2020-07-22 · Sale · Disposed 400 · Balance 228,893 F3: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 400 shares in multiple trades at prices ranging from $65.16 to $65.82. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Row 7 · 2020-07-22 · Sale · Disposed 4,228 · Balance 224,665 F4: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 4,228 shares in multiple trades at prices ranging from $66.21 to $67.19. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Row 8 · 2020-07-22 · Sale · Disposed 3,798 · Balance 220,867 F5: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 3,798 shares in multiple trades at prices ranging from $67.21 to $67.80. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Row 9 · 2020-07-22 · Exercise / conversion · Acquired 3,774 · Balance 224,641 Row 10 · 2020-07-22 · Sale · Disposed 1,151 · Balance 223,490 F6: On July 21, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 1,151 shares in multiple trades at prices ranging from $65.76 to $66.75. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Row 11 · 2020-07-22 · Sale · Disposed 2,623 · Balance 220,867 F7: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 2,623 shares in multiple trades at prices ranging from $66.79 to $67.64. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Row 12 · 2020-07-22 · Exercise / conversion · Acquired 30,772 · Balance 251,639 Row 13 · 2020-07-22 · Sale · Disposed 1,380 · Balance 250,259 F8: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 1,380 shares in multiple trades at prices ranging from $65.00 to $65.92. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Row 14 · 2020-07-22 · Sale · Disposed 12,217 · Balance 238,042 F9: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 12,217 shares in multiple trades at prices ranging from $66.03 to $67.02. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Row 15 · 2020-07-22 · Sale · Disposed 17,175 · Balance 220,867 F10: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 17,175 shares in multiple trades at prices ranging from $67.04 to $67.94. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. |
| Options to Buy Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $11.46 · Expires 2026-02-24 | Direct | 8,426 |
Reported balance
After 2020-07-21 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2020-07-21 · Exercise / conversion · Disposed 300 · Balance 8,426 F11: Fully vested as of the date hereof. |
| Options to Buy Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $21.15 · Expires 2028-02-26 | Direct | 98,358 |
Reported balance
After 2020-07-21 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2020-07-21 · Exercise / conversion · Disposed 3,021 · Balance 98,358 F12: Fully-vested as of the date hereof except for options to purchase 67,586 ordinary shares, which will vest in equal installments on each of 2/26/21 and 2/26/22, subject to the reporting person's continued employment through such dates. |
| Options to Buy Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $11.46 · Expires 2026-02-24 | Direct | 0 |
Reported balance
After 2020-07-22 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2020-07-22 · Exercise / conversion · Disposed 8,426 · Balance 0 F11: Fully vested as of the date hereof. |
| Options to Buy Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $11.46 · Expires 2026-02-24 | Direct | 0 |
Reported balance
After 2020-07-22 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2020-07-22 · Exercise / conversion · Disposed 3,774 · Balance 0 F11: Fully vested as of the date hereof. |
| Options to Buy Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $21.15 · Expires 2028-02-26 | Direct | 67,586 |
Reported balance
After 2020-07-22 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2020-07-22 · Exercise / conversion · Disposed 30,772 · Balance 67,586 F13: Options to purchase 67,586 ordinary shares will vest and become exercisable in equal installments on each of 2/26/21 and 2/26/22, subject to the reporting person's continued employment through such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 21, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 300 shares in multiple trades at prices ranging from $65.00 to $65.11. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
F2: On July 21, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 3,021 shares in multiple trades at prices ranging from $65.00 to $65.31. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
F3: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 400 shares in multiple trades at prices ranging from $65.16 to $65.82. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
F4: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 4,228 shares in multiple trades at prices ranging from $66.21 to $67.19. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
F5: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 3,798 shares in multiple trades at prices ranging from $67.21 to $67.80. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
F6: On July 21, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 1,151 shares in multiple trades at prices ranging from $65.76 to $66.75. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
F7: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 2,623 shares in multiple trades at prices ranging from $66.79 to $67.64. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
F8: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 1,380 shares in multiple trades at prices ranging from $65.00 to $65.92. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
F9: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 12,217 shares in multiple trades at prices ranging from $66.03 to $67.02. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
F10: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 17,175 shares in multiple trades at prices ranging from $67.04 to $67.94. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
F11: Fully vested as of the date hereof.
F12: Fully-vested as of the date hereof except for options to purchase 67,586 ordinary shares, which will vest in equal installments on each of 2/26/21 and 2/26/22, subject to the reporting person's continued employment through such dates.
F13: Options to purchase 67,586 ordinary shares will vest and become exercisable in equal installments on each of 2/26/21 and 2/26/22, subject to the reporting person's continued employment through such dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2019 Filed Jan 11, 2019 16:18 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 75,000 | $40.00 | $3,000,000.00 |
DisclosureSEC source: 0001209191-19-003415 · doc4.xml · nonDerivative · entry 2 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,558 F2 · price: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| January 09, 2019 Filed Jan 11, 2019 16:18 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 75,000 | $14.37 | $1,077,750.00 |
DisclosureSEC source: 0001209191-19-003415 · doc4.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares were acquired pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 16:08 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 29,565 | $0.00 Strike: $7.48 | $0.00 |
DisclosureSEC source: 0001209191-18-041549 · doc4.xml · derivative · entry 5 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 29,565 shares Expires 2024-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 16:08 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 27,825 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001209191-18-041549 · doc4.xml · derivative · entry 4 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 27,825 shares Expires 2023-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 16:08 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 57,390 | $31.48 | $1,806,637.20 |
DisclosureSEC source: 0001209191-18-041549 · doc4.xml · nonDerivative · entry 3 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,558 F2 · price: On July 2, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 57,390 shares in multiple trades at prices ranging from $31.00 to $31.95. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 16:08 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 29,565 | $7.48 | $221,146.20 |
DisclosureSEC source: 0001209191-18-041549 · doc4.xml · nonDerivative · entry 2 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,948 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares were acquired pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 16:08 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 27,825 | $7.03 | $195,609.75 |
DisclosureSEC source: 0001209191-18-041549 · doc4.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares were acquired pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| May 01, 2018 Filed May 3, 2018 16:34 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 11,305 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001209191-18-027652 · doc4.xml · derivative · entry 7 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,890 Underlying: Ordinary Shares · 11,305 shares Expires 2023-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| May 01, 2018 Filed May 3, 2018 16:34 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 20,000 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001209191-18-027652 · doc4.xml · derivative · entry 6 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,195 Underlying: Ordinary Shares · 20,000 shares Expires 2023-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| May 01, 2018 Filed May 3, 2018 16:34 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 20,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001209191-18-027652 · doc4.xml · derivative · entry 5 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 20,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| May 01, 2018 Filed May 3, 2018 16:34 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 8,695 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001209191-18-027652 · doc4.xml · derivative · entry 4 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 8,695 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| May 01, 2018 Filed May 3, 2018 16:34 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 60,000 | $27.40 | $1,644,000.00 |
DisclosureSEC source: 0001209191-18-027652 · doc4.xml · nonDerivative · entry 3 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,558 F2 · price: On May 1, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 60,000 shares in multiple trades at prices ranging from $26.925 to $27.825. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 01, 2018 Filed May 3, 2018 16:34 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 31,305 | $7.03 | $220,074.15 |
DisclosureSEC source: 0001209191-18-027652 · doc4.xml · nonDerivative · entry 2 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| May 01, 2018 Filed May 3, 2018 16:34 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 28,695 | $3.44 | $98,710.80 |
DisclosureSEC source: 0001209191-18-027652 · doc4.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| April 26, 2018 Filed Apr 30, 2018 17:56 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 20,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001209191-18-026910 · doc4.xml · derivative · entry 6 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,695 Underlying: Ordinary Shares · 20,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| April 26, 2018 Filed Apr 30, 2018 17:56 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 328 | $26.05 | $8,544.40 |
DisclosureSEC source: 0001209191-18-026910 · doc4.xml · nonDerivative · entry 5 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,558 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| April 26, 2018 Filed Apr 30, 2018 17:56 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,300 | $26.03 | $111,907.50 |
DisclosureSEC source: 0001209191-18-026910 · doc4.xml · nonDerivative · entry 4 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,886 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| April 26, 2018 Filed Apr 30, 2018 17:56 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,800 | $26.01 | $46,818.00 |
DisclosureSEC source: 0001209191-18-026910 · doc4.xml · nonDerivative · entry 3 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,186 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| April 26, 2018 Filed Apr 30, 2018 17:56 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 13,572 | $26.00 | $352,872.00 |
DisclosureSEC source: 0001209191-18-026910 · doc4.xml · nonDerivative · entry 2 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,986 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| April 26, 2018 Filed Apr 30, 2018 17:56 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 20,000 | $3.44 | $68,800.00 |
DisclosureSEC source: 0001209191-18-026910 · doc4.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| April 18, 2018 Filed Apr 19, 2018 16:54 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 20,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001209191-18-025605 · doc4.xml · derivative · entry 10 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,695 Underlying: Ordinary Shares · 20,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| April 18, 2018 Filed Apr 19, 2018 16:54 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 20,000 | $24.00 | $480,000.00 |
DisclosureSEC source: 0001209191-18-025605 · doc4.xml · nonDerivative · entry 8 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,558 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| April 18, 2018 Filed Apr 19, 2018 16:54 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 20,000 | $3.44 | $68,800.00 |
DisclosureSEC source: 0001209191-18-025605 · doc4.xml · nonDerivative · entry 7 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 16:54 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 20,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001209191-18-025605 · doc4.xml · derivative · entry 9 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,695 Underlying: Ordinary Shares · 20,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 16:54 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 545 | $22.21 | $12,104.45 |
DisclosureSEC source: 0001209191-18-025605 · doc4.xml · nonDerivative · entry 6 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,558 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 16:54 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,255 | $22.10 | $27,740.52 |
DisclosureSEC source: 0001209191-18-025605 · doc4.xml · nonDerivative · entry 5 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,103 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 16:54 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,000 | $22.10 | $44,200.00 |
DisclosureSEC source: 0001209191-18-025605 · doc4.xml · nonDerivative · entry 4 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,358 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 16:54 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 15,900 | $22.05 | $350,595.00 |
DisclosureSEC source: 0001209191-18-025605 · doc4.xml · nonDerivative · entry 3 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,358 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 16:54 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 300 | $22.00 | $6,600.00 |
DisclosureSEC source: 0001209191-18-025605 · doc4.xml · nonDerivative · entry 2 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,258 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 16:54 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 20,000 | $3.44 | $68,800.00 |
DisclosureSEC source: 0001209191-18-025605 · doc4.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 16:37 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 49,728 | $0.00 Strike: $0.23 | $0.00 |
DisclosureSEC source: 0001209191-18-020885 · doc4.xml · derivative · entry 2 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 49,728 shares Expires 2019-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested and currently exercisable as of the date hereof. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 16:37 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 49,728 | $0.23 | $11,437.44 |
DisclosureSEC source: 0001209191-18-020885 · doc4.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 16:14 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Stock Unit · Derivative | 18,519 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-014981 · doc4.xml · derivative · entry 2 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,519 Underlying: Ordinary Shares · 18,519 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one (1) ordinary share. F3 · derivative.exercise_date: One-third of these restricted stock units are scheduled to vest on each of February 27, 2019, 2020 and 2021, subject to the reporting person's continued employment through such dates. F3 · derivative.expiration_date: One-third of these restricted stock units are scheduled to vest on each of February 27, 2019, 2020 and 2021, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 16:14 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 135,172 | $0.00 Strike: $21.15 | $0.00 |
DisclosureSEC source: 0001209191-18-014981 · doc4.xml · derivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,172 Underlying: Ordinary Shares · 135,172 shares Expires 2028-02-27 F1 · derivative.exercise_date: Options to buy 135,172 ordinary shares will vest and become exercisable in equal installments on each of February 27, 2019, 2020, 2021 and 2022, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 23, 2018 Filed Feb 26, 2018 17:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 8,458 | $19.83 | $167,705.22 |
DisclosureSEC source: 0001209191-18-013430 · doc4.xml · nonDerivative · entry 2 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,830 F1 · price: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the Issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 17:13 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 31,201 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-013430 · doc4.xml · derivative · entry 3 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,399 Underlying: Ordinary Shares · 31,201 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 17:13 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 31,201 | $21.55 | $672,381.55 |
DisclosureSEC source: 0001209191-18-013430 · doc4.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 16:14 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 50,000 | $0.00 Strike: $0.23 | $0.00 |
DisclosureSEC source: 0001209191-18-008432 · doc4.xml · derivative · entry 2 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,087 Underlying: Ordinary Shares · 50,000 shares Expires 2019-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested and currently exercisable as of the date hereof. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 16:14 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 50,000 | $0.23 | $11,500.00 |
DisclosureSEC source: 0001209191-18-008432 · doc4.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2017 Filed Nov 6, 2017 16:17 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 900 | $22.00 | $19,800.00 |
DisclosureSEC source: 0001209191-17-059403 · doc4.xml · nonDerivative · entry 2 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,087 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 16:17 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 300 | $22.00 | $6,600.00 |
DisclosureSEC source: 0001209191-17-059403 · doc4.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,987 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| November 01, 2017 Filed Nov 2, 2017 16:19 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 24,227 | $22.01 | $533,163.59 |
DisclosureSEC source: 0001209191-17-058834 · doc4.xml · nonDerivative · entry 2 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,287 F2 · price: On November 1, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 24,227 shares in multiple trades at prices ranging from $22.00 to $22.075. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 31, 2017 Filed Nov 2, 2017 16:19 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 100 | $22.00 | $2,200.00 |
DisclosureSEC source: 0001209191-17-058834 · doc4.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,514 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| September 25, 2017 Filed Sep 27, 2017 16:16 UTC | NovoCure Ltd NVCR · Entity 4494 | Disposition to issuerOrdinary Shares | 3,200 | $22.05 | $70,554.88 |
DisclosureSEC source: 0001209191-17-054124 · doc4.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,614 F1 · price: On September 25, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 3,200 shares in multiple trades at prices ranging from $22.00 to $22.05. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 19, 2017 Filed Sep 21, 2017 16:23 UTC | NovoCure Ltd NVCR · Entity 4494 | Disposition to issuerOrdinary Shares | 3,200 | $22.00 | $70,400.00 |
DisclosureSEC source: 0001209191-17-053605 · doc4.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,814 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| September 14, 2017 Filed Sep 15, 2017 16:04 UTC | NovoCure Ltd NVCR · Entity 4494 | Disposition to issuerOrdinary Shares | 1,746 | $22.00 | $38,417.06 |
DisclosureSEC source: 0001209191-17-052948 · doc4.xml · nonDerivative · entry 2 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,014 F2 · price: On September 14, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 1,746 shares in multiple trades at prices ranging from $22.00 to $22.05. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 16:04 UTC | NovoCure Ltd NVCR · Entity 4494 | Disposition to issuerOrdinary Shares | 76,327 | $22.02 | $1,680,522.09 |
DisclosureSEC source: 0001209191-17-052948 · doc4.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,760 F1 · price: On September 13, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 76,327 shares in multiple trades at prices ranging from $22.00 to $22.10. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 16:43 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 1,395 | $6.67 | $9,308.84 |
DisclosureSEC source: 0001209191-17-044402 · doc4.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,087 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2017 through June 30, 2017. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 3, 2017. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 16:07 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Stock Unit · Derivative | 93,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-005224 · doc4.xml · derivative · entry 2 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,600 Underlying: Ordinary Shares · 93,600 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one (1) ordinary share. F3 · derivative.exercise_date: One-third of these restricted stock units are scheduled to vest on each of February 22, 2018, February 22, 2019, and February 22, 2020, subject to Mr. Ambrogi's continued employment through such dates. F3 · derivative.expiration_date: One-third of these restricted stock units are scheduled to vest on each of February 22, 2018, February 22, 2019, and February 22, 2020, subject to Mr. Ambrogi's continued employment through such dates. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 16:07 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 234,000 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0000899243-17-005224 · doc4.xml · derivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,000 Underlying: Ordinary Shares · 234,000 shares Expires 2027-02-22 F1 · derivative.exercise_date: Options to buy 234,000 ordinary shares will vest and become exercisable in equal installments on each of February 22, 2018, 2019, 2020 and 2021, subject to Mr. Ambrogi's continued employment through such dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.